Top-Rated StocksTop-RatedNASDAQ:CMPS Compass Pathways (CMPS) Stock Price, News & Analysis $14.82 +1.24 (+9.13%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$14.68 -0.14 (-0.91%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Compass Pathways Stock (NASDAQ:CMPS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Compass Pathways alerts:Sign Up Key Stats Today's Range$13.34▼$14.9450-Day Range$6.66▼$14.8252-Week Range$2.61▼$14.94Volume5.48 million shsAverage Volume3.39 million shsMarket Capitalization$2.00 billionP/E RatioN/ADividend YieldN/APrice Target$23.10Consensus RatingBuy Company Overview Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration. In addition to its lead depression program, Compass Pathways is exploring broader applications of psychedelic-assisted therapies in areas such as anorexia nervosa and other mood disorders. The company has built a scalable manufacturing process for synthetic psilocybin and established a network of trained therapists and research sites across Europe and North America. Compass also leverages digital tools to capture patient-reported outcomes and physiological data, supporting personalized treatment protocols and enhancing safety monitoring throughout clinical studies. Since its initial public offering in September 2020, Compass Pathways has advanced its pipeline through rigorous clinical partnerships and academic collaborations. The leadership team is led by co-founder and CEO George Goldsmith, who has guided the company through regulatory milestones and strategic alliances. With a board of directors comprising experts in neuroscience, clinical research, and life sciences commercialization, Compass remains committed to transforming the treatment paradigm for mental health by combining innovative science, patient-centered care, and robust regulatory engagement. AI Generated. May Contain Errors. Read More Compass Pathways Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreCMPS MarketRank™: Compass Pathways scored higher than 61% of companies evaluated by MarketBeat, and ranked 352nd out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingCompass Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCompass Pathways has a consensus price target of $23.10, representing about 55.9% upside from its current price of $14.82.Amount of Analyst CoverageCompass Pathways has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Compass Pathways' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compass Pathways are expected to decrease in the coming year, from ($1.24) to ($1.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Pathways is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Pathways is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Compass Pathways' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.37% of the float of Compass Pathways has been sold short.Short Interest Ratio / Days to CoverCompass Pathways has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Compass Pathways has recently increased by 14.03%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompass Pathways does not currently pay a dividend.Dividend GrowthCompass Pathways does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.59 News SentimentCompass Pathways has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Compass Pathways this week, compared to 4 articles on an average week.Search InterestOnly 13 people have searched for CMPS on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows11 people have added Compass Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compass Pathways insiders have not sold or bought any company stock.Percentage Held by Insiders2.82% of the stock of Compass Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of Compass Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Pathways' insider trading history. Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Pathways and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMPS Stock News HeadlinesCompass Pathways (NASDAQ:CMPS) Hits New 1-Year High Following Analyst UpgradeJune 27 at 1:21 AM | americanbankingnews.comA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This YearJune 26 at 9:30 AM | prnewswire.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.June 28 at 1:00 AM | Investors Alley (Ad)Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Average Recommendation of "Buy" by BrokeragesJune 23, 2026 | americanbankingnews.comIs COMPASS Pathways plc (CMPS) A Good Stock To Buy Now?June 11, 2026 | insidermonkey.comCOMPASS Pathways plc (CMPS) Fell Despite Earnings Beat and Faster Deal ClosureJune 5, 2026 | uk.finance.yahoo.comCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | businesswire.comCompass Pathways: A Psychedelics StoryMay 29, 2026 | seekingalpha.comSee More Headlines CMPS Stock Analysis - Frequently Asked Questions How have CMPS shares performed this year? Compass Pathways' stock was trading at $6.90 at the start of the year. Since then, CMPS shares have increased by 114.8% and is now trading at $14.82. How were Compass Pathways' earnings last quarter? Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) issued its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. Read the conference call transcript. When did Compass Pathways IPO? Compass Pathways (CMPS) raised $112 million in an initial public offering on Friday, September 18th 2020. The company issued 7,500,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Compass Pathways' major shareholders? Top institutional investors of Compass Pathways include Eagle Health Investments LP (1.53%), Orbimed Advisors LLC (0.89%), Affinity Asset Advisors LLC (0.86%) and Ally Bridge Group NY LLC (0.77%). Insiders that own company stock include Life Sciences NV Atai, Ekaterina Malievskaia and George Jay Goldsmith. View institutional ownership trends. How do I buy shares of Compass Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compass Pathways own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Pathways investors own include Symbotic (SYM), Enovix (ENVX), Rambus (RMBS), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings5/13/2026Today6/28/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 CMPS's financial health is in the Green zone, according to TradeSmith. CMPS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMPS CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees120Year Founded2016Price Target and Rating Average Price Target for Compass Pathways$23.10 High Price Target$70.00 Low Price Target$14.00 Potential Upside/Downside+55.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($3.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$287.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.07% Return on Assets-11.40% Debt Debt-to-Equity Ratio0.15 Current Ratio3.32 Quick Ratio3.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.55) per share Price / Book-26.95Miscellaneous Outstanding Shares134,950,000Free Float131,143,000Market Cap$2.00 billion OptionableOptionable Beta2.50 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CMPS) was last updated on 6/28/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, a 20-something broker named Irving Weiss shorted the market before Black Monday and made a fortune. H...Weiss Ratings | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredGold to $4,900—Here’s the Real PlayGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredFour winners over 400%. Here's #5CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...Golden Portfolio | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Pathways With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPS Stock Alerts